News GSK wagers $750m on Chimagen multiple myeloma therapy GSK has continued a drive to bulk up its pipeline, taking global rights to a T-cell engager for multiple myeloma, developed by China's Chimagen Bio.
News Hutchmed rises on $1.3bn KRAS licensing deal with GSK GSK has paid Hutchmed $110m upfront for rights to a preclinical KRAS and EGFR-directed drug with potential in colorectal, pancreatic, and lung cancer.
News Roche taps Simcere for autoimmune trispecific for $1.53bn Roche is paying $75m upfront for a trispecific drug developed by China's Simcere Zaiming for B-cell-mediated autoimmune disorders and blood cancers.
News Sobi adds rare lymphoma drug with $580m Innate tie-up Sobi chief executive Guido Oelkers is preparing his exit, but is still cutting deals, licensing a lymphoma drug from Innate for up to $580m.
News UK's Mission divests kidney drug to Dimerix for $292m Mission Therapeutics has struck a deal to out-license a drug for acute kidney injury to Australia's Dimerix, sharpening its focus on CNS diseases.
News Spero snaps up Innovent immunology drug in strategic pivot Spero has licensed rights to an anti-CD40L antibody developed by China's Innovent, in a $1.1bn deal that signals a shift away from antimicrobial R&D.
News GSK gets second cancer drug approval from Nuvalent buy The FDA has cleared GSK's ALK inhibitor Nelkarmi for a form of lung cancer, the second product from its $10.6bn acquisition of Nuvalent.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.